Premium
Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study
Author(s) -
Ekbom K.,
Monstad I.,
Prusinski A.,
Cole J. A.,
Pilgrim A. J.,
Noronha D.
Publication year - 1993
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1993.tb04189.x
Subject(s) - tolerability , placebo , sumatriptan , medicine , cluster headache , anesthesia , adverse effect , migraine , crossover study , agonist , alternative medicine , receptor , pathology
This multicentre, double‐blind, randomised, crossover study compared the efficacy, safety and tolerability of subcutaneous sumatriptan (6 mg and 12 mg) with placebo in 134 in‐patients with cluster headache. Headache improvement to mild or no pain at 5, 10 and 15 min after treatment was recorded. At 10 min, headache relief was reported by 25% placebo), 49% (6 mg) and 63% (12 mg) of patients and at 15 min the results were 35% (placebo), 75% (6 mg) and 80% (12 mg) (p < 0.001 for all comparisons with placebo). The 12 mg dose was not significantly better than the 6 mg dose and was associated with more adverse events. The 6 mg dose is therefore recommended for the acute treatment of cluster headache.